“Shkreli awards” recognise most egregious profiteering in US healthcare

Abstract:

his is the eighth year in which the awards have been given. Winners are chosen by a panel including doctors, public health experts, journalists, and patient advocates. The awards are named after Martin Shkreli, the “pharma bro” who became infamous when he bought the maker of the anti-parasitic drug Daraprim and increased the price 50-fold.

Speaking at the ceremony, Lown Institute president Vikas Saini said, “All these stories paint a picture of a healthcare industry in desperate need of transformation. Doing these awards every year shows us that this is nothing new.”